3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Ovarian Neoplasms
17
Fallopian Tube Neoplasms
15
Breast Neoplasms
7
Sarcoma
5
Neoplasm Metastasis
4
Carcinoma, Ovarian Epithelial
4
Neoplasms
3
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multi-centric Castleman's Disease
2
Hodgkin Disease
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Osteosarcoma
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphadenopathy
1
Interventions
pembrolizumab
1
liposomal doxorubicin
1
atezolizumab
1
Tumor Necrosis Factor-alpha
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoviridae Infections
×
liposomal doxorubicin
×
90 days
×
Clear all
NCT05271318
2026-05-05
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2
Active not recruiting
29 enrolled